Yoshida I, Saito AM, Tanaka S, et al. - Via performing a multicenter, open‐label, randomized, non‐inferiority trial, researchers sought to compare the safety and efficacy of intravenous itraconazole (ivITCZ) and liposomal amphotericin B (LAmB) as empirical antifungal therapy in cases with hematological malignancies with neutropenia and persistent fever. They randomized eligible patients to receive treatment with LAmB (3.0 mg /kg /day) or ivITCZ (induction: 400 mg /day, maintenance: 200 mg /day). Outcomes revealed similar efficacy and safety profile of ivITCZ vs LAmB as empirical antifungal therapy in hematological malignancy patients with febrile neutropenia. The small sample size and various limitations, however, prevented demonstration of its non‐inferiority.